The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
出版年份 2023 全文链接
标题
The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 22, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-25
DOI
10.1186/s12933-023-01743-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults
- (2022) Pasquale Mone et al. Cardiovascular Diabetology
- Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
- (2022) Carly Adamson et al. CIRCULATION
- Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
- (2022) Michael Böhm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases
- (2021) Charles Khouri et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- (2021) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
- (2021) Chu Lin et al. Cardiovascular Diabetology
- Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
- (2021) Meir Schechter et al. Cardiovascular Diabetology
- Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
- (2021) Jordi Real et al. Cardiovascular Diabetology
- Low Blood Pressure and Managing Drugs in HF
- (2021) Nicolas Girerd JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
- (2021) Xiang Zhou et al. Frontiers in Pharmacology
- Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes
- (2021) Min Zhuo et al. JAMA Network Open
- Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
- (2020) Jiali Liu et al. DIABETES OBESITY & METABOLISM
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
- (2020) Antonios Douros et al. ANNALS OF INTERNAL MEDICINE
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fracture Risk After Initiation of Use of Canagliflozin
- (2019) Michael Fralick et al. ANNALS OF INTERNAL MEDICINE
- SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission
- (2019) Peter S Hamblin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men
- (2019) Chintan V. Dave et al. JAMA Internal Medicine
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
- (2019) Felipe A. Martinez et al. CIRCULATION
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- (2019) Gian Paolo Fadini et al. BMJ Open Diabetes Research & Care
- Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
- (2019) Avivit Cahn et al. DIABETES CARE
- Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study
- (2018) Young-Gun Kim et al. Cardiovascular Diabetology
- SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
- (2018) Charles Khouri et al. DIABETES OBESITY & METABOLISM
- Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems
- (2018) E. Raschi et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
- (2017) Gian Paolo Fadini et al. Lancet Diabetes & Endocrinology
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
- (2017) Michiru Nishita et al. Scientific Reports
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
- (2013) R Harpaz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
- (2011) G Niklas Norén et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now